[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Joslin Diabetes Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,75,95,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100613780","nutrition-effect-of-a-high-protein-diabetes-formula-on-body-composition-in-type-2-diabetes-patients-treated-with-incretin-mimetics-100613780",false,"NCT07271043","Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics","Evaluating the Efficacy of High-Protein Diabetes Specific Formula (HP-DSF) on Body Composition in Overweight\u002FObese Patients With Type 2 Diabetes Treated With Incretin Mimetic Drugs","Inclusion Criteria:\n\n1. Subject is between 18-75 years of age\n2. Subject was diagnosed with type 2 diabetes at least 3 months prior to screening\n3. Subject is about to start treatment with an IMD, a GLP-1 receptor agonist (RA) alone or a dual GLP-1\u002FGIP RA. These treatments include either semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), or dulaglutide (Trulicity®)\n4. Body mass index (BMI) is ≥ 25 kg\u002Fm2\n\nExclusion Criteria:\n\n1. Subject has type 1 diabetes mellitus\n2. Subject with estimated glomerular filtration rate \\\u003C60 milliliters\u002Fminute\u002F1.73 m²,\n3. Urine albumin-to-creatinine ratio (UACR) of 300 mg\u002Fg or higher\n4. History of acute kidney injury (AKI) during the 6 months prior to screening g.\n5. Intolerance or allergy to HP-DSF shake or to any of its ingredients\n6. Women who are pregnant or lactating or expect to be pregnant or lactating during the study period.\n7. Women of childbearing potential who are not using highly effective contraceptive methods.\n\n   \\-","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","A randomized clinical study to assess the efficacy of a high-protein diabetes specific formula (HPDSF) on lean muscle mass in overweight and obese patients with type 2 diabetes who are initiating treatment with incretin-mimetic drugs.",[27],"Type 2 Diabetes","RECRUITING","2026-05-27",{"date":31,"type":32},"2026-05-29","ACTUAL",{"date":34,"type":32},"2026-01-01",{"date":36,"type":21},"2026-12-01",{"name":38,"class":39},"Joslin Diabetes Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100628903","postnatal-exercise-to-activate-babys-brown-fat-100628903","NCT07467694","Postnatal Exercise to Activate Baby's Brown Fat","Impact of Acute Exercise and Habitual Physical Activity on Human Milk Composition and Childhood Obesity Risk","PEABaBy","Inclusion Criteria:\n\n* 18-45 y of age at the time of enrollment\n* Pre-gravid or first trimester BMI 18.5 -40 kg\u002Fm2\n* Uncomplicated singleton pregnancy\n* Intention to exclusively breastfeed for \\>3 months and, if parity \\>1, that they successfully breastfed a previous pregnancy\n* Term pregnancy (gestational age 37 to \\\u003C42 weeks)\n* Infant with birth weight \\>10th percentile of weight for gestational age\n\nExclusion Criteria:\n\n* Any obstetric contra-indication to exercise at 1 month\n* Diagnosis of uncontrolled (HbA1c \\>7%) type 1 or type 2 diabetes, or gestational diabetes managed with insulin\n* Intrauterine growth restriction\n* Pre-eclampsia or other pregnancy complications\n* Alcohol, cannabis or tobacco use\n* Known congenital metabolic, endocrine disease, or congenital illness affecting infant feeding\u002Fgrowth\n* Major fetal anomalies\n* Musculoskeletal issues that would make exercise difficult",true,"FEMALE","45 Years",{"count":53,"type":21},200,[24],"The purpose of this study is to learn how exercise and physical activity during pregnancy and after pregnancy may affect the composition of breastmilk. Certain changes in breast milk after exercise may have an impact on how infants use energy. Understanding this process may improve public health recommendations for exercise during and after pregnancy. This study can help investigators learn more about how maternal exercise patterns may affect body growth and obesity risk in infants who are breastfed. This research may help identify how different factors can influence healthy weight and early development in infants.",[57,58,59,60,61,62,63],"Childhood Obesity Prevention","Childhood Obesity","Physical Activity","Lactation","Breastfeeding","Pregnancy","Exercise",[60,61,65,62,63],"Breast milk","2026-03-11",{"date":68,"type":32},"2026-03-12",{"date":70,"type":32},"2025-12-01",{"date":72,"type":21},"2030-07-01",{"name":38,"class":39},2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100628941","diabetes-body-project-2-100628941","NCT07468188","Diabetes Body Project 2","Development of a T2D-Specific, Virtually-Delivered Disordered Eating Prevention Intervention - Diabetes Body Project 2","Inclusion Criteria:\n\n* 1.) Female sex 2) self-reported gender identity of \"woman\"; 3) age 18-40 years old; 4) diagnosed with T2D for at least 6 months; 5) experiencing at least one body image concern.\n\nExclusion Criteria:\n\n* Recent hospitalization for eating disorder within the last 12 months\n* Eating disorder related diabetic ketoacidosis within the last 12 months\n* unwillingness to be video-recorded,\n* restricted English proficiency\n* developmental, cognitive, or psychiatric limitations that compromise participation in the intervention sessions and study.","40 Years",{"count":84,"type":21},42,[24],"The purpose of this study is to test the feasibility and effectiveness of an eating disorder prevention program specifically targeted for women with type 2 diabetes (T2D) called the Diabetes Body Project 2 (DBP2).\n\nThe Diabetes Body Project 2 (DBP2) will be adapted from the Diabetes Body Project, which is an eating disorder prevention program developed to improve satisfaction with body image and diabetes management for young women with type 1 diabetes (DBP).\n\nThe study is looking to see if the DBP is effective in improving body image concerns, reducing disordered eating behaviors and improving glycemic control in women with T2D.",[88,27],"Eating Disorders",{"date":68,"type":32},{"date":91,"type":32},"2025-01-24",{"date":93,"type":21},"2027-05-31",{"name":38,"class":39},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100599283","external-carotid-blood-flow-in-individuals-with-post-bariatric-hypoglycemia-100599283","NCT07082478","External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia","External Carotid Blood Flow Dynamics in Individuals With Post-Bariatric Hypoglycemia (PBH): Pilot Study","Inclusion Criteria:\n\n* Age 18-70 years of age, inclusive at screening.\n* Individuals able to provide informed consent and follow all study procedures, including complete daily food, activity, and symptom diaries, and willingness to provide access to medical record review.\n* For healthy control group: individuals without a history of upper gastrointestinal surgery and without reported symptoms of hypoglycemia.\n* Individuals with access to personal iPhone running operating system 16 (iOS) or later versions (not feasible for Android platform users) and a password-protected home Wi-Fi network.\n\nExclusion Criteria:\n\n* History of coronary artery disease or presence of 2 or more risk factors including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use.\n* History of myocardial infarction, unstable angina or revascularization within the past 6 months.\n* History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia.\n* Documented hypoglycemia occurring in the fasting state (\\> 12 hours fast).\n* Concurrent administration of β-blocker therapy.\n* Vigorous physical activity within 24 hours prior to assessment.\n* Seizure disorder (other than with suspect or documented hypoglycemia).\n* Hematocrit \\\u003C 33% (women) or \\\u003C36% (men) within the past 6 months.\n* History of insulinoma.\n* Use of central nervous system-active medications, including: antidepressants, anxiolytics, antipsychotics, stimulants, antiepileptics, sedatives and opioids.\n* History of severe neurologic vascular disease (e.g. cerebrovascular disease\u002Fstroke).\n* History of previous diseases associated with dysautonomia (e.g. multiple system atrophy, multiple sclerosis, Parkinson's disease).\n* Impaired hepatic function (aspartate amino transaminase and\u002For alanine amino transaminase \\>2x upper limit of normal range), as determined within the past 6 months.\n* Impaired renal function (serum creatinine \\>1.5 mg\u002FdL), as determined within the past 6 months.\n* Serious psychiatric or substance abuse disorders (e.g. alcohol, opioid, cocaine use disorder), as judged by the study investigator.\n* Non-consent or inability to comply with study procedures.\n* Current pregnancy and\u002F or lactation.\n* Vulnerable individuals (e.g., fetuses, children, prisoners) and those judged by the investigator to be unsuitable for the study.\n* Individuals wearing earrings or other jewelry in the left ear who are unable or unwilling to remove them for the duration of the study.\n* Unwillingness to wear study masked CGM for duration of study","70 Years",{"count":5,"type":21},"OBSERVATIONAL","This is a pilot study (small-scale study) that aims to understand more about how blood flow changes in people who have low blood sugar after bariatric surgery (post-bariatric hypoglycemia) compared to those who have had surgery without hypoglycemia, those who have hypoglycemia without surgery, or those who do not experience low blood sugar.\n\nThis study has two phases. This is the first phase, and the purpose is to test comfort and feasibility of a novel in-ear wearable device (Lumia Health) that measures blood flow changes to the head. Information from the study will help the investigators determine if the device is suitable to be used in the second phase of the study.",[107,108],"Hypoglycemia","Cerebral Blood Flow",[110,111,112,113,114],"hypoglycemia","postprandial hypoglycemia","bariatric surgery","autonomic dysfunction","cerebral blood flow","2025-11-26",{"date":117,"type":32},"2025-11-28",{"date":119,"type":32},"2025-07-28",{"date":121,"type":21},"2026-09-15",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":40},"100555378","exercise-brain-activity-and-weight-maintenance-100555378","NCT06511310","Exercise, Brain Activity, and Weight Maintenance","Effects of Exercise Training on Brain Activity and Its Relation to Weight Maintenance and Appetite Regulation","Inclusion Criteria:\n\n* Age 18-70 years\n* Body mass index (BMI) \\>19 kg\u002Fm2 and body weight\\\u003C 250kg\n* Participants must have experienced a clinically significant weight regain, defined as over 10% of their maximum weight lost, within 1 to 5 years following their bariatric surgery. They will be asked to self-report their weight loss history. Participants must also provide the operative report from their bariatric surgery for reference.\n* In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations\n* Willing to adhere to the protocol requirements for the duration of the study\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Peripheral neuropathy with insensate feet\n* Recent blood donation within the last 2 months\n* Use of beta-blockers\n* Current pregnancy or breastfeeding\n* Active Heart or lung disease\n* Severe hypertension (systolic \\>160 mmHg or diastolic \\>90 mmHg)\n* Inability to exercise for any reason\n* Any known contraindication to exercise testing based on current ACSM guidelines\n* MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body\n* Known presence of a structural brain lesion (e.g. tumor, cortical infarct)\n* Presence of another neurologic disorder, which could impact findings (e.g. multiple sclerosis)\n* History of cardiovascular disease, stroke, congestive heart failure\n* Active hematological, renal, pulmonary or hepatic disorders\n* Active treatment for cancer\n* A history of active alcohol or substance abuse\n* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol\n* History of claustrophobia and inability to tolerate an MRI\n* Body weight \\>250kgr and largest body diameter of 70cm as there is a certain weight and diameter limit of the MRI scanner\n* Unwilling or unable to return for study visits, undergo neuropsychological testing and MRI imaging\n* Left-handedness",{"count":131,"type":21},15,[24],"This study aims to explore how HIIT influences brain function, neural and molecular pathways related to weight control, setting the stage for future obesity intervention research.",[135,136,137,138],"Obesity","Weight Gain","Bariatric Surgery Candidate","Appetitive Behavior","2025-08-27",{"date":141,"type":32},"2025-09-04",{"date":143,"type":21},"2025-09-15",{"date":145,"type":21},"2027-07-01",{"name":38,"class":39},""]